SCHEMBL146497

SCHEMBL146497

O=C(c1cc2cc(Br)ccc2s1)N1CC(N2CC(N3Cc4ccccc4C3=O)C2)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 1/20 0.49
MEN1 O00255 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
KDM5A P29375 1/20 0.39
HRH4 Q9H3N8 1/20 0.38
LMNA P02545 1/20 0.37
DPP4 P27487 1/20 0.37
DPP8 Q6V1X1 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.35
MTR Q99707 1/20 0.34
ALDH1A1 P00352 3/20 0.33
HDAC6 Q9UBN7 2/20 0.33
F10 P00742 1/20 0.33
GAA P10253 3/20 0.32
KDM4E B2RXH2 2/20 0.32
GLA P06280 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
HPGD P15428 1/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL143941 0.93 MGLL (0.49) MGLLRAB9AKDM5AHRH4DPP4
SCHEMBL145401 0.88 MGLL (0.48) MGLLKDM5AHRH4DPP4DPP8
SCHEMBL121366 0.83 MGLL (0.63) MGLLRAB9AKDM5ADPP4DPP8
SCHEMBL146774 0.83 MGLL (0.48) MGLLKDM5AHRH4DPP4DPP8
SCHEMBL146020 0.82 MGLL (0.43) MGLLKDM5AHRH4DPP4DPP8
SCHEMBL121564 0.81 MGLL (0.51) MGLLKDM5AHRH4DPP4DPP8
SCHEMBL149492 0.80 MGLL (0.58) MGLLKDM5AL3MBTL1MTRALDH1A1
SCHEMBL142482 0.79 MGLL (0.45) MGLLMEN1RAB9AKMT2AKDM5A
SCHEMBL146953 0.77 MGLL (0.43) MGLLKDM5AHRH4DPP4DPP8
SCHEMBL143096 0.75 MGLL (0.54) MGLLMEN1KMT2AKDM5AMTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2611774-B1 DI-AZETIDINYL DIAMIDE AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2015-03-18 EP disclosed
US-8759533-B2 Di-azetidinyl diamide as monoacylglcerol lipase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2014-06-24 US disclosed
US-8759333-B2 Di-azetidinyl diamide as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2014-06-24 US disclosed
US-20130196968-A1 DI-AZETIDINYL DIAMIDE AS MONOACYLGLCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA, NV (BE) 2013-08-01 US disclosed
US-20130196969-A1 DI-AZETIDINYL DIAMIDE AS MONOACYLGLCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA, NV (BE) 2013-08-01 US disclosed
US-20120058986-A1 DI-AZETIDINYL DIAMIDE AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2012-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130196969-A1 DI-AZETIDINYL DIAMIDE AS MONOACYLGLCEROL LIPASE INHIBITORS MGLL, PNLIP, LPL MGLL 1/4885MEN1 2640/4885RAB9A 776/4885
US-20130196968-A1 DI-AZETIDINYL DIAMIDE AS MONOACYLGLCEROL LIPASE INHIBITORS MGLL, PNLIP, LPL MGLL 1/4885MEN1 2640/4885RAB9A 776/4885
US-20120058986-A1 DI-AZETIDINYL DIAMIDE AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, LIPA MGLL 4/4885MEN1 3178/4885RAB9A 944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.